Search

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

Key updates

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Top-line data now expected to be announced in Q1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness

Key Updates

LEIDEN, the Netherlands, Sept. 14, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that PQ-010-002 is open for enrollment.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.